Stoke Therapeutics Executives Sell Shares to Cover Tax Liabilities and Other Reasons
Executives at Stoke Therapeutics, including Edward M. Kaye, Barry Ticho, and Allan Jonathan, sold shares to cover tax liabilities. Kaye sold 2,136 shares for $64,541, Ticho sold 4,020 shares for $121,468, and Jonathan sold 4,576 shares for $138,268. These transactions occurred on December 2 and 3, 2025, with prices ranging from $28.93 to $31.17 per share.
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Kaye Edward M. Md | Director, 10% Owner | Sell | $64,541 | Form 4 |
| Ticho Barry | CHIEF MEDICAL OFFICER, 10% Owner | Sell | $121,468 | Form 4 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC, 10% Owner | Sell | $138,268 | Form 4 |
Edward M. Kaye, a director and 10% owner at Stoke Therapeutics, sold 2,136 shares of common stock on December 2 and 3, 2025, at weighted average prices ranging from $29.562 to $30.8477 per share, totaling $64,541, to satisfy tax withholding liabilities. Following these transactions, Kaye directly owns 51,305 shares of the company.
Barry Ticho, the Chief Medical Officer and a 10% owner of Stoke Therapeutics, sold 4,020 shares of common stock across four transactions on the same dates, for a total of $121,468, at weighted average prices between $29.562 and $30.8477 per share. After these sales, Ticho directly owns 15,156 shares.
Allan Jonathan, General Counsel & Corporate Secretary and a 10% owner, sold 4,576 shares on December 2 and 3, 2025, at weighted average prices from $28.93 to $31.17 per share, resulting in a total sale amount of $138,268, to cover tax liabilities related to restricted stock units. Post-transaction, Jonathan directly owns 19,612 shares of Stoke Therapeutics.
